OM Pharma enters into worldwide exclusive agreement on triacyls, including OM-197-MP-AC and OM-294-DP, with an important European pharmaceutical company
February 25th, 2008

Meyrin/Geneva, OM Pharma announces today that it has signed an exclusive global license agreement for synthetic triacyl compounds, including OM-197-MP-AC and OM-294-DP with an undisclosed important European pharmaceutical company.

These novel TLR4 agonists are strong activators of human dendritic cells. Such activity is crucial to the role played by immunological adjuvants for the development of prophylactic and therapeutic vaccines in allergology and other indications. In addition to an advanced preclinical pharmacology programme, these molecules also have a good safety profile, designed to allow their use in phase I clinical trials.

Top of the page